Leerink Partners Boosts Revolution Medicines (NASDAQ:RVMD) Price Target to $171.00

Key Points

• Leerink Partners raised its price target on Revolution Medicines to $171 (from $147) and maintained an "outperform" rating, implying roughly a 19.8% upside from the prior close.
• Phase‑3 RASolute‑302 topline results reportedly showed statistically significant overall survival and progression‑free survival benefits for daraxonrasib versus chemotherapy, with detailed data due at ASCO—bolstering the drug’s commercial and regulatory prospects.
• Despite the positive news, the company remains unprofitable with a recent EPS miss and there has been substantial insider selling, which could create near‑term downside or investor caution.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) had its price objective upped by equities research analysts at Leerink Partners from $147.00 to $171.00 in a note issued to investors on Wednesday,Benzinga reports. The brokerage presently has an "outperform" rating on the stock. Leerink Partners' price objective suggests a potential upside of 19.83% from the company's previous close.

RVMD has been the subject of several other reports. Benchmark reaffirmed an "overweight" rating on shares of Revolution Medicines in a research note on Tuesday, February 17th. Wedbush reaffirmed an "outperform" rating on shares of Revolution Medicines in a research note on Tuesday, April 14th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Revolution Medicines in a research note on Thursday, January 22nd. Truist Financial raised shares of Revolution Medicines to a "strong-buy" rating in a research note on Wednesday, March 25th. Finally, Stifel Nicolaus reissued a "buy" rating on shares of Revolution Medicines in a research note on Monday. Four research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, Revolution Medicines presently has a consensus rating of "Buy" and an average target price of $84.06.

Revolution Medicines Price Performance

NASDAQ:RVMD traded down $6.19 during midday trading on Wednesday, hitting $142.71. The company had a trading volume of 420,533 shares, compared to its average volume of 3,480,848. Revolution Medicines has a 52-week low of $34.00 and a 52-week high of $155.70. The stock's fifty day moving average price is $105.17 and its 200-day moving average price is $87.90. The company has a market capitalization of $28.28 billion, a PE ratio of -24.19 and a beta of 1.01. The company has a quick ratio of 7.14, a current ratio of 7.14 and a debt-to-equity ratio of 0.16.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last announced its earnings results on Wednesday, February 25th. The company reported ($1.86) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.56) by ($0.30). During the same period in the prior year, the firm posted ($1.12) EPS. As a group, research analysts expect that Revolution Medicines will post -7.69 earnings per share for the current year.

Insiders Place Their Bets

In other Revolution Medicines news, insider Stephen Michael Kelsey sold 4,302 shares of the company's stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $99.48, for a total value of $427,962.96. Following the sale, the insider owned 295,398 shares in the company, valued at approximately $29,386,193.04. This represents a 1.44% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Xiaolin Wang sold 2,010 shares of the company's stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $99.48, for a total transaction of $199,954.80. Following the completion of the sale, the insider owned 116,063 shares in the company, valued at approximately $11,545,947.24. This trade represents a 1.70% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 184,592 shares of company stock valued at $24,499,532. Insiders own 8.20% of the company's stock.

Institutional Investors Weigh In On Revolution Medicines

A number of institutional investors have recently made changes to their positions in RVMD. Nextech Invest Ltd. boosted its holdings in Revolution Medicines by 20.7% in the fourth quarter. Nextech Invest Ltd. now owns 7,601,087 shares of the company's stock worth $332,472,000 after purchasing an additional 1,304,347 shares during the last quarter. Millennium Management LLC boosted its holdings in Revolution Medicines by 681.8% in the first quarter. Millennium Management LLC now owns 156,353 shares of the company's stock worth $5,529,000 after purchasing an additional 136,353 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in Revolution Medicines by 14.2% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 300,196 shares of the company's stock worth $10,615,000 after purchasing an additional 37,345 shares during the last quarter. Invesco Ltd. boosted its holdings in Revolution Medicines by 19.3% in the second quarter. Invesco Ltd. now owns 227,019 shares of the company's stock worth $8,352,000 after purchasing an additional 36,760 shares during the last quarter. Finally, Jump Financial LLC boosted its holdings in Revolution Medicines by 87.9% in the second quarter. Jump Financial LLC now owns 15,258 shares of the company's stock worth $561,000 after purchasing an additional 7,137 shares during the last quarter. Hedge funds and other institutional investors own 94.34% of the company's stock.

Key Headlines Impacting Revolution Medicines

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: Phase‑3 RASolute‑302 topline results reportedly showed a statistically significant overall survival (OS) and progression‑free survival (PFS) benefit for daraxonrasib vs standard chemotherapy; detailed results will be presented in a plenary session at ASCO (May 31). This is material clinical validation that supports the drug’s commercial/regulatory potential. ASCO Plenary Announcement
• Positive Sentiment: Updated Phase 1/2 clinical data for daraxonrasib (first‑line metastatic PDAC) and preclinical data on RM‑055 were accepted for presentation at AACR — continued positive data flow across the pipeline supports long‑term upside. AACR Data Release
• Positive Sentiment: Analyst support remains strong: multiple firms have buy/outperform ratings (HC Wainwright, Stifel, others) and recent median price targets sit above the current level, which underpins upside expectations. Analyst Consensus
• Neutral Sentiment: Daraxonrasib holds FDA Breakthrough and Orphan Drug designations and is in multiple registrational programs — these designations speed review but do not guarantee approval or commercialization timing. Quiver Summary
• Negative Sentiment: Significant insider selling has been reported (dozens of sales, no recent insider purchases), which can signal founder/exec liquidity or trigger investor concern about near‑term selling pressure. Insider / Institutional Activity
• Negative Sentiment: Large institutional trimming by several major managers in recent quarters has reduced a portion of the ownership base, which can exacerbate downside on news or during profit‑taking. Institutional Moves
• Negative Sentiment: Recent quarterly results missed EPS expectations and the company remains unprofitable — clinical success is a high bar and regulatory/commercial risks remain; investors often de‑risk positions until full datasets and safety profiles are presented. Earnings Context / Coverage

About Revolution Medicines

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company's research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.